TITLE

Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial

PUB. DATE
October 2009
SOURCE
PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p18
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports on the positive outcome of the psoriasis trial of Israel-based biopharmaceutical firm Can-Fite Biopharma Ltd. The 75-patient Phase II double-blind clinical study of the anti-TNF drug CF101 in patients with moderate to severe psoriasis resulted to efficacy upon oral administration in 35% of the subjects. Accordingly, it was found that the small molecule CF101 is a promising oral anti-TNF agent that provides a well tolerated and safe therapeutic approach against the disease.
ACCESSION #
44767509

 

Related Articles

  • Therapy explosion. SCHWANKE, JANE // Dermatology Times;Aug2005, Vol. 26 Issue 8, p28 

    The article suggests various therapies used in the treatment of psoriasis. The various procedures used includes T-cell drugs Raptiva(efalizumab, Biogen), the best therpy for treating psoriasis, granuloma annulare, lichenplanus, alopecia areata and atopic dermatitis. The article also discourses...

  • CLINIC ROUNDUP.  // BioWorld Today;9/17/2009, Vol. 20 Issue 179, p9 

    The article offers news briefs related to pharmaceutical industry. Israel-based Can-Fite BioPharma completed its Phase II study on CF101 drug designed to cure psoriasis. The Seattle, Washington-based Cell Therapeutics Inc. accomplished its purpose in the Phase III study called EXTEND aimed at...

  • Clinic Roundup.  // BioWorld Today;8/2/2011, Vol. 22 Issue 148, p7 

    The article reports on the enrollment in a Phase II/III trial of CF101, a drug for psoriasis, developed by Can-Fite BioPharma Ltd.

  • Dermatology.  // CenterWatch Weekly;4/6/2015, Vol. 19 Issue 13, p9 

    This article discusses the results of a phase II/III trial by pharmaceutical company Can-Fite BioPharma on the efficacy of the drug CF101 in patients with moderate-to-severe plaque psoriasis.

  • DERMATOLOGICAL DISORDERS.  // Monthly Prescribing Reference;Feb2011, Vol. 27 Issue 2, p122 

    A part of the book "Monthly Prescribing Reference" for February 2011 is presented. It offers an overview of pharmacological treatments for dermatological disorders including acne, psoriasis and skin infections. The drugs include Aczone from Allergan, Neoral from Novartis and Abreva from...

  • A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease Severity. van de Kerkhof, P. C. M.; Wasel, N.; Kragballe, K.; Cambazard, F.; Murray, S. // Dermatology (10188665);2005, Vol. 210 Issue 4, p294 

    Background: A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet®/Dovobet®) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psoriasis vulgaris. Objective: To determine the effectiveness of the...

  • CLINIC ROUNDUP.  // BioWorld Today;6/5/2007, Vol. 18 Issue 108, p3 

    The article offers news briefs on issues related to medicine trials. Acorda Therapeutics Inc. has presented a meta-analysis of data on 501 multiple sclerosis patients from two clinical trials of Fampridine-SR. Bionovo Inc. has released mixed results from its double-blind, placebo-controlled,...

  • Other News To Note.  // BioWorld Today;6/7/2011, Vol. 22 Issue 109, p4 

    This section offers news briefs concerning the biotechnology sector as of June 2011. Aradigm Corp. received a U.S. Food and Drug Administration (FDA) orphan designation for ciprofloxacin for inhalation for the management of bronchiectasis. Can-Fite BioPharma Ltd. agreed to spin off its...

  • CLINIC ROUNDUP.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p3 

    This section offers news briefs on clinical trials. Clinical research organization (CRO) Accelovance Inc. was selected by Amarillo Biosciences Inc. for a human clinical study of the company's oral interferon product for influenza in the U.S. A trial of CF101 to treat patients with moderate to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics